Rilzabrutinib Becomes First FDA-Approved BTK Inhibitor for ITP
The FDA has approved rilzabrutinib (Wayrilz; Sanofi) as a groundbreaking treatment for immune thrombocytopenia (ITP), enhancing patient outcomes and quality of life.